Managing Bone Health in Breast Cancer
Published Online: Wednesday, February 5, 2014
For High-Definition, ClickDenosumab and zoledronic acid are the two main therapies available for the prevention of declines in bone health and skeletal-related events for patients with breast cancer, explains moderator Adam M. Brufsky, MD, PhD. Moreover, in addition to the impact of these agents on bone health, they may also improve disease-free survival and overall survival, Brufsky suggests.
A meta-analysis presented at the San Antonio Breast Cancer Symposium explored the impact of bisphosphonate treatment on recurrence and cause-specific mortality for patients with breast cancer. In this large analysis, treatment with a bisphosphonate was associated with a statistically significant 17% reduction in the risk of death and an overall 3.1% decrease in mortality rates. However, practice is rarely changed by meta-analyses, Hope S. Rugo, MD, states. In general, the primary use for these agents will remain focused on maintaining bone health.
In general, the panelists prefer prescribing denosumab, due to its administration route and efficacy. However, Joyce A. O'Shaughnessy, MD, states that both treatments are equal in terms of their effectiveness.
View More From This Discussion
Most Popular Right Now
Online CME Activities
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.